Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking
Journal of Pharmacy and Pharmacology · 09.06.2025 · 77 (6) · 805-821
DOI: 10.1093/jpp/rgae141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 16.12.2024. Verfasst von Yuan Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical R…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drugs, Chinese Herbal, Lung Neoplasms, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key R&D Plan of Shaanxi Province.
Abstract (Originalsprache)
Objective
This study aimed to explore the mechanism of Taohong Siwu decoction (THSWD) in the treatment of non-small-cell lung cancer (NSCLC) by using comprehensive analysis.
Methods
The active components and relevant targets of THSWD were analyzed by network analysis to construct the active component-target-disease network diagram. Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted on the core targets by the Metascape database. Molecular docking verification was used for molecular visualization. Key findings A total of 69 active compounds and 114 targets were filtered in lung cancer treatment with THSWD. KEGG analysis suggested that tumor necrosis factor (TNF) signaling pathway, and apoptosis pathway played critical roles. The results of molecular docking showed that populoside_qt with IL-6, baicalein with epidermal growth factor receptor (EGFR), and luteolin with MAPK8 had the strongest binding ability. Moreover, experiment validation revealed that THSWD regulated the expression of IL-6, AKT, Cyclin D1, E-cadherin, and LC3A/B, thereby inhibiting the proliferation and migration ability, promoting apoptosis, and blocking the cell cycle of NSCLC cells.
Conclusions
The potential targets and molecular mechanisms of THSWD in the treatment of NSCLC were preliminarily revealed by a comprehensive analysis in this study, which will provide new ideas and methods for the study of the mechanism of traditional Chinese medicine in treating lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Orthodontics, School o…
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, 712046, China.
ORCID-Profile: Yuan Qin
Förderung
- National Natural Science Foundation of China
- Key R&D Plan of Shaanxi Province
Zitieren
APA
Qin, Y., Lian, J. N., Chen, X., Huang, F. Y., Chen, H. W., Dong, T. W., & Jin, Z. L. (2025). Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking. Journal of Pharmacy and Pharmacology, 77(6), 805-821. https://doi.org/10.1093/jpp/rgae141
Vancouver
Qin Y, Lian JN, Chen X, Huang FY, Chen HW, Dong TW, et al. Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking. Journal of Pharmacy and Pharmacology. 2025;77(6):805-821. doi:10.1093/jpp/rgae141
BibTeX
@article{Qin2025,
author = {Qin, Yuan and Lian, Jia-Ning and Chen, Xin and Huang, Feng-Yu and Chen, Hai-Wen and Dong, Tai-Wei and Jin, Zuo-Lin},
title = {Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
volume = {77},
number = {6},
pages = {805--821},
doi = {10.1093/jpp/rgae141}
}
EUVIMED